Laminar shear stress therapy for Glaucoma: Laminar shear stress therapy increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 28/March/2017, 12.23 am

Natural product-derived therapy for Diabetic Kidney disease: Salvianolic acid A, isolated from Salvia Miltiorrhiza Bunge, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene, 28/February/2017, 12.10 am
May 27, 2017
Natural product-derived therapy for Chronic Myeloid leukaemia (CML): Agaricus Blazei Murill (AbM) decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloic leukemia via up-regulation of its target gene, 28/May/2017, 10.45 pm
May 28, 2017
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General science” with an I.F of 34.661] by Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Laminar shear stress therapy for Glaucoma: Laminar shear stress therapy increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene

price-quote[easy_payment currency=”USD”]


From significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glucosma has no cure; (4) vision lost due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

Figure 1. Mechanistic insights into how Laminar shear stress therapy alleviates glucoma.  Laminar shear stress therapy, by increasing the expression of its target gene, enhances NAD+ levels and improves glaucoma

This study suggests, for the first time, a natural product based therapy for Glaucoma. Laminar shear stress therapy, by increasing the expression of its target gene, it may increase the expression of Nmnat1. Thereby, it may: (1) increase NAD+ levels; (2) decrease Intraocular pressure; (3) improve pressure-induced damage; and (4) alleviate glaucoma (Fig.1).

Thus, physicians/ophthalmologists may consider adapting Laminar shear stress therapy in the treatment of glaucoma. Taken together, Laminar shear stress therapy may be used to  Glaucoma.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Laminar shear stress therapy increase the levels of NAD+ to prevent glaucoma?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Laminar shear stress therapy for Glaucoma: Laminar shear stress therapy increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 28/March/2017, 12.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.